Ardelyx Inc (ARDX)
NASDAQ:ARDX
Want to see ARDX full AI Analyst Report?
ARDX Stock Chart & Stats
$6.45
-$0.17(-3.14%)
At close: 4:00 PM EST
$6.45
-$0.17(-3.14%)
Day’s Range― - ―
52-Week Range$3.49 - $8.40
Previous CloseN/A
Volume1.36M
Average Volume (3M)3.97M
Market Cap
$1.51B
Enterprise Value$1.69B
Total Cash (Recent Filing)$238.07M
Total Debt (Recent Filing)$208.26M
Price to Earnings (P/E)―
Beta0.77
Next Earnings
Jul 30, 2026EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.24
Shares Outstanding247,029,390
10 Day Avg. Volume3,549,801
30 Day Avg. Volume3,968,875
Financial Highlights & Ratios
PEG Ratio-0.43
Price to Book (P/B)8.42
Price to Sales (P/S)3.45
P/FCF Ratio-31.96
Enterprise Value/Market Cap1.12
Enterprise Value/Revenue3.94
Enterprise Value/Gross Profit4.29
Enterprise Value/Ebitda-49.53
Forecast
1Y Price Target
$16.50Price Target Upside155.81% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.05
Revenue Forecast (FY)$545.48M
Bulls Say, Bears Say
Bulls Say
Clinical ExpansionInitiation of a Phase 3 study to evaluate the lead drug in chronic idiopathic constipation could broaden labeled uses and substantially increase the addressable patient population.
Commercial ExecutionGrowing prescription trends combined with an expanded salesforce and enhanced patient assistance programs suggest improved prescription conversion and higher future sales for the lead products.
Intellectual PropertyA newly allowed formulation patent listed in the FDA Orange Book could extend commercial exclusivity for the constipation drugs, strengthening long-term revenue visibility.
Bears Say
Commercial Adoption RiskAmbitious growth targets rely on broad prescriber adoption of new initiatives, and failure to achieve sufficient uptake could undermine projected revenue momentum.
Payer Coverage RiskLack of expected Medicare Part D coverage for Xphozah could limit access for insured patients and constrain that product's market penetration.
Regulatory And Legal RiskRemaining regulatory hurdles and the potential need for additional legal clarity on the new patent could delay commercialization or prompt costly litigation that would weigh on valuation.
Ardelyx News
ARDX FAQ
What was Ardelyx Inc’s price range in the past 12 months?
Ardelyx Inc lowest stock price was $3.49 and its highest was $8.40 in the past 12 months.
What is Ardelyx Inc’s market cap?
Ardelyx Inc’s market cap is $1.51B.
When is Ardelyx Inc’s upcoming earnings report date?
Ardelyx Inc’s upcoming earnings report date is Jul 30, 2026 which is in 67 days.
How were Ardelyx Inc’s earnings last quarter?
Ardelyx Inc released its earnings results on Apr 30, 2026. The company reported -$0.15 earnings per share for the quarter, missing the consensus estimate of -$0.142 by -$0.008.
Is Ardelyx Inc overvalued?
According to Wall Street analysts Ardelyx Inc’s price is currently Undervalued.
Does Ardelyx Inc pay dividends?
Ardelyx Inc does not currently pay dividends.
What is Ardelyx Inc’s EPS estimate?
Ardelyx Inc’s EPS estimate is -0.04.
How many shares outstanding does Ardelyx Inc have?
Ardelyx Inc has 247,029,390 shares outstanding.
What happened to Ardelyx Inc’s price movement after its last earnings report?
Ardelyx Inc reported an EPS of -$0.15 in its last earnings report, missing expectations of -$0.142. Following the earnings report the stock price went up 8.689%.
Which hedge fund is a major shareholder of Ardelyx Inc?
Currently, no hedge funds are holding shares in ARDX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ardelyx Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$16.50 (155.81% Upside)
$16.50 (155.81% Upside)
Blogger Sentiment
Bullish
ARDX Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $901.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.5%
Last 30 Days ▲ 8.3%
Last 30 Days ▲ 8.3%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
54.29%
12-Months-Change
Fundamentals
Return on Equity
-38.11%
Trailing 12-Months
Asset Growth
22.99%
Trailing 12-Months
Company Description
Ardelyx Inc
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. The company has agreements with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
ARDX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented multiple strong operational and commercial achievements — notably robust Ibsrela growth (58% YoY), solid product revenue expansion (+38% total product revenue), active pipeline advancement (EXCEL Phase 3 initiated with rapid site activation), improved net loss versus prior year, and strengthened financial optionality via debt refinancing and $238M in cash. Headwinds include elevated and growing OpEx tied to commercialization and Phase 3 activity, GAAP reporting complexity for Exposa due to prior‑year adjustments, Q1 seasonality and storm‑related disruptions, and near‑term gross‑to‑net pressure. On balance the company reiterated mid‑ and long‑term revenue targets and appears confident in execution, though profitability and competitive risk remain items to monitor.View all ARDX earnings summariesARDX Stock 12 Month Forecast
Average Price Target
$16.50
▲(155.81% Upside)
Technical Analysis
Vericel
―
Viridian Therapeutics
―
Dianthus Therapeutics
―
Pharvaris
―
Edgewise Therapeutics
―
Ownership Overview
3.66% Insiders
22.52% Mutual Funds
11.20% Other Institutional Investors
48.54% Public Companies and
Individual Investors